Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies

Retrovirology

Volumn 6, Issue , 2009, Pages

  Dieltjens, Tessa ^a   Heyndrickx, Leo ^a   Willems, Betty ^a   Gray, Elin ^b   Van Nieuwenhove, Lies ^a   Grupping, Katrijn ^a   Vanham, Guido ^a,c   Janssens, Wouter ^a  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^c UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 4E10; VIRUS RNA; EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEUTRALIZING ANTIBODY; PEPTIDE LIBRARY; VIRUS ANTIBODY; VIRUS ENVELOPE PROTEIN;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIBODY SPECIFICITY; ARTICLE; CASE REPORT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOGENICITY; MALE; NONHUMAN; PHAGE DISPLAY; RNA ISOLATION; VIRUS ENVELOPE; VIRUS IMMUNITY; VIRUS NEUTRALIZATION; VIRUS RESISTANCE; BLOOD; DISEASE COURSE; GENETICS; HOST PATHOGEN INTERACTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOLOGY; MOLECULAR GENETICS; PATHOLOGY; SEQUENCE ANALYSIS;

HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS;

AIDS VACCINES; AMINO ACID SEQUENCE; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; DISEASE PROGRESSION; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; EPITOPES, B-LYMPHOCYTE; HIV INFECTIONS; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, HUMORAL; MALE; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; RNA, VIRAL; SEQUENCE ANALYSIS, RNA;

EID: 74049152949     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-6-113     Document Type: Article

References (52)

1. Moog C, Fleury HJ, Pellegrin I, Kirn A, Aubertin AM. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. J Virol 1997, 71:3734-3741. 191523, 9094648.
2. Nyambi PN, Lewi P, Peeters M, Janssens W, Heyndrickx L, Fransen K, Andries K, Haesevelde M, Heeney J, Piot P, Groen G. Study of the dynamics of neutralization escape mutants in a chimpanzee naturally infected with the simian immunodeficiency virus SIVcpz-ant. J Virol 1997, 71:2320-2330. 191341, 9032368.
3. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ, Burton DR. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004, 78:13232-13252. 10.1128/JVI.78.23.13232-13252.2004, 524984, 15542675.
4. Ferrantelli F, Rasmussen RA, Buckley KA, Li PL, Wang T, Montefiori DC, Katinger H, Stiegler G, Anderson DC, McClure HM, Ruprecht RM. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. J Infect Dis 2004, 189:2167-2173. 10.1086/420833, 15181562.
5. Ruprecht RM, Ferrantelli F, Kitabwalla M, Xu W, McClure HM. Antibody protection: passive immunization of neonates against oral AIDS virus challenge. Vaccine 2003, 21:3370-3373. 10.1016/S0264-410X(03)00335-9, 12850342.
6. Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, Bleeker WK, Parren PW, Marx PA, Burton DR. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat Med 2009, 15:951-954. 10.1038/nm.1974, 19525965.
7. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, Burton DR. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009, 5:e1000433. 10.1371/journal.ppat.1000433, 2674935, 19436712.
8. Trkola A, Kuster H, Rusert P, Joos B, Fischer M, Leemann C, Manrique A, Huber M, Rehr M, Oxenius A, Weber R, Stiegler G, Vcelar B, Katinger H, Aceto L, Günthard HF. Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat Med 2005, 11:615-622. 10.1038/nm1244, 15880120.
9. Bower JF, Li Y, Wyatt R, Ross TM. HIV-1 Envgp140 trimers elicit neutralizing antibodies without efficient induction of conformational antibodies. Vaccine 2006, 24:5442-5451. 10.1016/j.vaccine.2006.03.063, 16621193.
10. Mascola JR, Snyder SW, Weislow OS, Belay SM, Belshe RB, Schwartz DH, Clements ML, Dolin R, Graham BS, Gorse GJ, Keefer MC, McElrath MJ, Walker MC, Wagner KF, McNeil JG, McCutchan FE, Burke DS. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis 1996, 173:340-348.
11. Dong M, Zhang PF, Grieder F, Lee J, Krishnamurthy G, VanCott T, Broder C, Polonis VR, Yu XF, Shao Y, Faix D, Valente P, Quinnan GV. Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system. J Virol 2003, 77:3119-3130. 10.1128/JVI.77.5.3119-3130.2003, 149731, 12584337.
12. Quinnan GV, Zhang PF, Fu DW, Dong M, Alter HJ. Expression and characterization of HIV type 1 envelope protein associated with a broadly reactive neutralizing antibody response. AIDS Res Hum Retroviruses 1999, 15:561-570. 10.1089/088922299311088, 10221533.
13. Zhang PF, Cham F, Dong M, Choudhary A, Bouma P, Zhang Z, Shao Y, Feng YR, Wang L, Mathy N, Voss G, Broder CC, Quinnan GV. Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proc Natl Acad Sci USA 2007, 104:10193-10198. 10.1073/pnas.0608635104, 1885220,1885220, 17540729.
14. Frey G, Peng H, Rits-Volloch S, Morelli M, Cheng Y, Chen B. A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc Natl Acad Sci USA 2008, 105:3739-3744. 10.1073/pnas.0800255105, 2268799, 18322015.
15. Humbert M, Rasmussen RA, Ong H, Kaiser FM, Hu SL, Ruprecht RM. Inducing cross-clade neutralizing antibodies against HIV-1 by immunofocusing. PLoS One 2008, 3:e3937. 10.1371/journal.pone.0003937, 2597739, 19081789.
16. Humbert M, Antoni S, Brill B, Landersz M, Rodes B, Soriano V, Wintergerst U, Knechten H, Staszewski S, von Laer D, Dittmar MT, Dietrich U. Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma. Eur J Immunol 2007, 37:501-515. 10.1002/eji.200636560, 17236253.
17. Scala G, Chen X, Liu W, Telles JN, Cohen OJ, Vaccarezza M, Igarashi T, Fauci AS. Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera. J Immunol 1999, 162:6155-6161.
18. Yuste E, Sanford HB, Carmody J, Bixby J, Little S, Zwick MB, Greenough T, Burton DR, Richman DD, Desrosiers RC, Johnson WE. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma. J Virol 2006, 80:3030-3041. 10.1128/JVI.80.6.3030-3041.2006, 1395451, 16501112.
19. Shen X, Parks RJ, Montefiori DC, Kirchherr JL, Keele BF, Decker JM, Blattner WA, Gao F, Weinhold KJ, Hicks CB, Greenberg ML, Hahn BH, Shaw GM, Haynes BF, Tomaras GD. In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J Virol 2009, 83:3617-3625. 10.1128/JVI.02631-08, 2663270, 19193787.
20. Davis D, Donners H, Willems B, Vermoesen T, Heyndrickx L, Colebunders R, Groen G. Epitopes corresponding to the envelope genetic subtype are present on the surface of free virions of HIV-1 group M primary isolates and can be detected in neutralization assays with extended incubation phases. J Med Virol 2003, 71:332-342. 10.1002/jmv.10490, 12966537.
21. Cardoso RM, Brunel FM, Ferguson S, Zwick M, Burton DR, Dawson PE, Wilson IA. Structural basis of enhanced binding of extended and helically constrained peptide epitopes of the broadly neutralizing HIV-1 antibody 4E10. J Mol Biol 2007, 365:1533-1544. 10.1016/j.jmb.2006.10.088, 17125793.
22. Cardoso RM, Zwick MB, Stanfield RL, Kunert R, Binley JM, Katinger H, Burton DR, Wilson IA. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 2005, 22:163-173. 10.1016/j.immuni.2004.12.011, 15723805.
23. Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E, Davis KL, Decker JM, Wycuff D, Harris L, Hawkins N, Wood B, Nathe C, Richman D, Tomaras GD, Bibollet-Ruche F, Robinson JE, Morris L, Shaw GM, Montefiori DC, Mascola JR. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 2008, 82:11651-11668. 10.1128/JVI.01762-08, 2583680, 18815292.
24. Li Y, Svehla K, Louder MK, Wycuff D, Phogat S, Tang M, Migueles SA, Wu X, Phogat A, Shaw GM, Connors M, Hoxie J, Mascola JR, Wyatt R. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol 2009, 83:1045-1059. 10.1128/JVI.01992-08, 2612402, 19004942.
25. Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, Caldwell Z, Yu X, Wood B, Self S, Kalams S, Stamatatos L. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 2009, 83:757-769. 10.1128/JVI.02036-08, 2612355, 18987148.
26. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, Robinson J, Scearce RM, Plonk K, Staats HF, Ortel TL, Liao HX, Alam SM. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005, 308:1906-1908. 10.1126/science.1111781, 15860590.
27. Scherer EM, Zwick MB, Teyton L, Burton DR. Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. Aids 2007, 21:2131-2139. 10.1097/QAD.0b013e3282a4a632, 18090039.
28. Asherson RA, Cervera R. Antiphospholipid antibodies and infections. Ann Rheum Dis 2003, 62:388-393. 10.1136/ard.62.5.388, 1754545, 12695147.
29. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, Ruker F, Katinger H. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993, 67:6642-6647. 238102, 7692082.
30. Zwick MB, Jensen R, Church S, Wang M, Stiegler G, Kunert R, Katinger H, Burton DR. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol 2005, 79:1252-1261. 10.1128/JVI.79.2.1252-1261.2005, 538539, 15613352.
31. Manrique A, Rusert P, Joos B, Fischer M, Kuster H, Leemann C, Niederost B, Weber R, Stiegler G, Katinger H, Günthard HF, Trkola A. In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J Virol 2007, 81:8793-8808. 10.1128/JVI.00598-07, 1951363, 17567707.
32. Gray ES, Moore PL, Bibollet-Ruche F, Li H, Decker JM, Meyers T, Shaw GM, Morris L. 4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response. J Virol 2008, 82:2367-2375. 10.1128/JVI.02161-07, 2258954, 18094155.
33. Pinter A, Honnen WJ, He Y, Gorny MK, Zolla-Pazner S, Kayman SC. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J Virol 2004, 78:5205-5215. 10.1128/JVI.78.10.5205-5215.2004, 400352, 15113902.
34. Gray ES, Taylor N, Wycuff D, Moore PL, Tomaras GD, Wibmer CK, Puren A, DeCamp A, Gilbert PB, Wood B, Montefiori DC, Binley JM, Shaw GM, Haynes BF, Mascola JR, Morris L. Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J Virol 2009, 83:8925-8937. 10.1128/JVI.00758-09, 19553335.
35. Enshell-Seijffers D, Smelyanski L, Vardinon N, Yust I, Gershoni JM. Dissection of the humoral immune response toward an immunodominant epitope of HIV: a model for the analysis of antibody diversity in HIV+ individuals. Faseb J 2001, 15:2112-2120. 10.1096/fj.00-0898com, 11641237.
36. Lu L, Zhu Y, Huang J, Chen X, Yang H, Jiang S, Chen YH. Surface exposure of the HIV-1 env cytoplasmic tail LLP2 domain during the membrane fusion process: interaction with gp41 fusion core. J Biol Chem 2008, 283:16723-16731. 10.1074/jbc.M801083200, 2423246, 18408000.
37. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003, 100:4144-4149. 10.1073/pnas.0630530100, 153062, 12644702.
38. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312. 10.1038/nature01470, 12646921.
39. Bunnik EM, Pisas L, van Nuenen AC, Schuitemaker H. Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. J Virol 2008, 82:7932-7941. 10.1128/JVI.00757-08, 2519599, 18524815.
40. Veiga AS, Pattenden LK, Fletcher JM, Castanho MA, Aguilar MI. Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems. Chembiochem 2009, 10:1032-1044. 10.1002/cbic.200800609, 19283693.
41. McCaffrey RA, Saunders C, Hensel M, Stamatatos L. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. J Virol 2004, 78:3279-3295. 10.1128/JVI.78.7.3279-3295.2004, 371088, 15016849.
42. Wang J, Sen J, Rong L, Caffrey M. Role of the HIV gp120 conserved domain 1 in processing and viral entry. J Biol Chem 2008, 283:32644-32649. 10.1074/jbc.M806099200, 2583318, 18815131.
43. Peleg O, Brunak S, Trifonov EN, Nevo E, Bolshoy A. RNA secondary structure and squence conservation in C1 region of human immunodeficiency virus type 1 env gene. AIDS Res Hum Retroviruses 2002, 18:867-878. 10.1089/08892220260190353, 12201910.
44. Sreepian A, Permmongkol J, Kantakamalakul W, Siritantikorn S, Tanlieng N, Sutthent R. HIV-1 neutralization by monoclonal antibody against conserved region 2 and patterns of epitope exposure on the surface of native viruses. J Immune Based Ther Vaccines 2009, 7:5. 10.1186/1476-8518-7-5, 2770445, 19821992.
45. Sreepian A, Srisurapanon S, Horthongkham N, Tunsupasawasdikul S, Kaoriangudom S, Khusmith S, Sutthent R. Conserved neutralizing epitopes of HIV type 1 CRF01_AE against primary isolates in long-term nonprogressors. AIDS Res Hum Retroviruses 2004, 20:531-542. 10.1089/088922204323087787, 15186528.
46. Gray ES, Madiga MC, Moore PL, Mlisana K, Abdool Karim SS, Binley JM, Shaw GM, Mascola JR, Morris L. Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J Virol 2009, 83:11265-11274. 10.1128/JVI.01359-09, 19692477.
47. Swadzba J, De Clerck LS, Stevens WJ, Bridts CH, van Cotthem KA, Musial J, Jankowski M, Szczeklik A. Anticardiolipin, anti-beta(2)-glycoprotein I, antiprothrombin antibodies, and lupus anticoagulant in patients with systemic lupus erythematosus with a history of thrombosis. J Rheumatol 1997, 24:1710-1715.
48. Harris EN, Gharavi AE, Patel SP, Hughes GR. Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986. Clin Exp Immunol 1987, 68:215-222. 1542695, 3652514.
49. Aarden LA, de Groot ER, Feltkamp TE. Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique. Ann N Y Acad Sci 1975, 254:505-515. 10.1111/j.1749-6632.1975.tb29197.x, 52321.
50. Fenyo EM, Heath A, Dispinseri S, Holmes H, Lusso P, Zolla-Pazner S, Donners H, Heyndrickx L, Alcami J, Bongertz V, Jassoy C, Malnati M, Montefiori D, Moog C, Morris L, Osmanov S, Polonis V, Sattentau Q, Schuitemaker H, Sutthent R, Wrin T, Scarlatti G. International network for comparison of HIV neutralization assays: the NeutNet report. PLoS One 2009, 4:e4505. 10.1371/journal.pone.0004505, 2640999, 19229336.
51. Beels D, Heyndrickx L, Vereecken K, Vermoesen T, Michiels L, Vanham G, Kestens L. Production of human immunodeficiency virus type 1 (HIV-1) pseudoviruses using linear HIV-1 envelope expression cassettes. J Virol Methods 2008, 147:99-107. 10.1016/j.jviromet.2007.08.014, 17904649.
52. Montefiori DC. Measuring HIV neutralization in a luciferase reporter gene assay. Methods Mol Biol 2009, 485:395-405. full_text, 19020839.